Free Trial
NASDAQ:BIVI

BioVie (BIVI) Stock Price, News & Analysis

BioVie logo
$2.15 +0.09 (+4.37%)
(As of 12/24/2024 05:19 PM ET)

About BioVie Stock (NASDAQ:BIVI)

Key Stats

Today's Range
$2.00
$2.17
50-Day Range
$1.12
$3.51
52-Week Range
$1.04
$33.10
Volume
530,574 shs
Average Volume
1.67 million shs
Market Capitalization
$38.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Buy

Company Overview

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

BioVie Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
24th Percentile Overall Score

BIVI MarketRank™: 

BioVie scored higher than 24% of companies evaluated by MarketBeat, and ranked 838th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioVie has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioVie has received no research coverage in the past 90 days.

  • Read more about BioVie's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioVie is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioVie is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioVie has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.36% of the outstanding shares of BioVie have been sold short.
  • Short Interest Ratio / Days to Cover

    BioVie has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioVie has recently increased by 36.30%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    BioVie does not currently pay a dividend.

  • Dividend Growth

    BioVie does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.36% of the outstanding shares of BioVie have been sold short.
  • Short Interest Ratio / Days to Cover

    BioVie has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioVie has recently increased by 36.30%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    Only 4 people have searched for BIVI on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added BioVie to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioVie insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.00% of the stock of BioVie is held by insiders.

  • Percentage Held by Institutions

    Only 4.59% of the stock of BioVie is held by institutions.

  • Read more about BioVie's insider trading history.
Receive BIVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioVie and its competitors with MarketBeat's FREE daily newsletter.

BIVI Stock News Headlines

BioVie files to sell 7.71M shares of common stock for holders
BioVie says Parkinson’s Disease clinical trial is fully funded
How Low-Cost Stocks Generate Monthly Income
Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!
BioVie Raises $3.24 Million in Direct Offering
BioVie 1.15M share registered direct offering priced at $2.83
See More Headlines

BIVI Stock Analysis - Frequently Asked Questions

BioVie's stock was trading at $1.26 at the start of the year. Since then, BIVI shares have increased by 70.6% and is now trading at $2.15.
View the best growth stocks for 2024 here
.

BioVie Inc. (NASDAQ:BIVI) posted its quarterly earnings results on Monday, September, 30th. The company reported ($6.60) earnings per share for the quarter.

Shares of BIVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioVie investors own include ARMOUR Residential REIT (ARR), AGNC Investment (AGNC), Hon Hai Precision Industry (HNHPF), Main Street Capital (MAIN), Ares Capital (ARCC) and PIMCO Dynamic Income Fund (PDI).

Company Calendar

Last Earnings
9/30/2024
Today
12/24/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BIVI
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+39.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-32,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.54 per share

Miscellaneous

Free Float
17,057,000
Market Cap
$38.20 million
Optionable
Optionable
Beta
0.40
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:BIVI) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners